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Robert K. Semple 3,1,2,*ABSTRACT
Objective: Insulin signalling via phosphoinositide 3-kinase (PI3K) requires PIK3R1-encoded regulatory subunits. C-terminal PIK3R1 mutations
cause SHORT syndrome, as well as lipodystrophy and insulin resistance (IR), surprisingly without fatty liver or metabolic dyslipidaemia. We sought
to investigate this discordance.
Methods: The human pathogenic Pik3r1 Y657* mutation was knocked into mice by homologous recombination. Growth, body composition,
bioenergetic and metabolic profiles were investigated on chow and high-fat diet (HFD). We examined adipose and liver histology, and assessed
liver responses to fasting and refeeding transcriptomically.
Results: Like humans with SHORT syndrome, Pik3r1WT/Y657* mice were small with severe IR, and adipose expansion on HFD was markedly
reduced. Also as in humans, plasma lipid concentrations were low, and insulin-stimulated hepatic lipogenesis was not increased despite
hyperinsulinemia. At odds with lipodystrophy, however, no adipocyte hypertrophy nor adipose inflammation was found. Liver lipogenic gene
expression was not significantly altered, and unbiased transcriptomics showed only minor changes, including evidence of reduced endoplasmic
reticulum stress in the fed state and diminished Rictor-dependent transcription on fasting. Increased energy expenditure, which was not
explained by hyperglycaemia nor intestinal malabsorption, provided an alternative explanation for the uncoupling of IR from dyslipidaemia.
Conclusions: Pik3r1 dysfunction in mice phenocopies the IR and reduced adiposity without lipotoxicity of human SHORT syndrome. Decreased
adiposity may not reflect bona fide lipodystrophy, but rather, increased energy expenditure, and we suggest that further study of brown adipose
tissue in both humans and mice is warranted.
 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Adipose tissue is essential for metabolic health in the face of sustained
positive energy balance. When adipose expansion is constrained, as in
lipodystrophy, its capacity to sequester excess energy and serve as a
physiological “energy buffer” is overwhelmed [1]. Injury and inflam-
mation of any residual adipose tissue ensues, causing systemic
inflammation and rerouting substrates to the liver, pancreas and
muscle. Insulin resistance (IR), diabetes, aggressive fatty liver disease,1The University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MR
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common consequences of lipodystrophy [2].
SHORT syndrome (short stature, hyperextensibility of joints, ocular
depression, Rieger anomaly of the iris, and teething delay) is a human
monogenic syndrome including lipodystrophy [3e5]. This form of
lipodystrophy is highly unusual - though associated with insulin
resistant diabetes [3e5], this is uncoupled from fatty liver and dysli-
pidaemia [6]. SHORT syndrome also does not feature the suppressed
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Original Articlelipodystrophies [7], proving that some elements of the “insulin resis-
tance syndrome” are dissociable.
SHORT syndrome is caused by mutations in PIK3R1; encoding com-
ponents of the insulin signalling enzyme phosphoinositide 3-kinase
(PI3K) [3e5]. The PI3K subtype required for insulin action comprises
a p110a catalytic subunit bound to a regulatory subunit, three (p85a,
p55a and p50a) of which are encoded by PIK3R1. PIK3R1 products
stabilise catalytic subunits, mediating their recruitment to receptor
tyrosine kinases or their substrates, including the insulin receptor and
IRS1 [8,9].
Before the discovery of PIK3R1 mutations in SHORT syndrome, Pik3r1
had been intensively studied in mice. Selective p85a deficiency [10,11]
or deletion of p50a and p55a [12] surprisingly enhances insulin
sensitivity, which has been accounted for by compensation by other
regulatory subunits, and/or altered stoichiometry of catalytic and regu-
latory subunits. A critical insight from the study of SHORT syndrome was
that the insulin signalling role of PIK3R1 could be severely attenuated by
neomorphic mutations disrupting the C-terminal SH2 domain [3e5].
Such dominant negative PIK3R1 alleles, which severely reduce insulin-
induced activation of PI3K without abolishing the expression of PI3K,
offer the opportunity to interrogate, more precisely than has been
possible to date, the in vivo pathophysiological roles of PI3K activity in IR.
In human lipodystrophy, de novo lipogenesis contributes significantly
to liver triglyceride and plasma lipid content [13]. In contrast, mutations
in the INSR gene encoding the insulin receptor produce extreme IR with
normal plasma lipid profile, normal liver lipid content, and no increase
in hepatic de novo lipogenesis [13]. Furthermore, murine models with
knockout of any one of several components of the insulin signalling
pathway (Insr [14], Irs1 and Irs2 [15], p85a and b [16], Pik3ca [17], or
Rictor [18]) demonstrate that liver insulin signalling drives hepatic de
novo lipogenesis. We thus hypothesised that in SHORT syndrome, the
liver is protected from increased insulin-mediated lipogenesis, which is
relatively unaffected by common IR [19], and that this explains the
absence of dyslipidaemia and fatty liver despite severe IR and
lipodystrophy.
We report a novel murine SHORT syndrome model caused by a human
pathogenic allele, Y657*, that reproduces uncoupling of metabolic
dyslipidaemia from severe IR. Surprisingly, hepatic lipogenic tran-
scriptional programmes were minimally perturbed, although metabolic
inflexibility with a dyscoordinated fasting response was seen. Adipose
tissue accumulation was reduced on high-fat feeding. We suggest that
this is related to increased energy expenditure, likely via brown adi-
pose tissue, rather than lipodystrophy, with hypolipidemia attributable
to increased fuel oxidation. This potential explanation for the unusual IR
subphenotype of SHORT syndrome warrants testing in humans with
SHORT syndrome or other proximal insulin signalling defects.
2. MATERIALS AND METHODS
2.1. Mice generation and maintenance
The Pik3r1 Y657* mutation and a neomycin resistance cassette
flanked by LoxP sites were introduced into C57Bl/6 embryonic stem
cells by homologous recombination before injection into Bl/6J blas-
tocysts (Supplemental Figure S1). Animals were kept on a C57Bl/6J
background, backcrossed at least three times, and housed on a 12-h-
light/12-h-dark cycle at 23 C, with ad libitum food and water access.
Feeding was with chow (Catalogue no. 105, Safe diets) or 45% fat diet
(45% fat, 35% Carbohydrate and 25% protein) (Catalogue no. D12451,
Research diet, Inc). Experiments were carried out under the UK Home
Office Animals (Scientific Procedures) Act 1986, following University of
Cambridge ethical review.2
 2020 The Authors. Published by Elsevier G2.2. Assessment of growth, body composition, and energy
homeostasis
Body composition was determined by time-domain NMR with Bruker’s
minispec analyser. For food intake and energy expenditure measure-
ment, male mice were acclimatized for 1 week to single housing then
given chow or 45% fat diet for 10 days. Food intake was measured daily
and energy expenditure measured by indirect calorimetry [20]. Loco-
motor activity was quantified as beam breaks over 48 h. Faecal energy
content wasmeasured by combusting dried faeces from 48 h calorimeter
runs in an IKA Calorimeters Oxygen Bomb calorimeter (IKA C1).
2.3. In vivo metabolic studies
In fasting/refeeding studies, mice were fed chow ad libitum until 16
weeks of age before 16 h fasting, then 6 h refeeding with chow.
Tissues were harvested and snap frozen prior to overnight fasting, or
after fasting or after refeeding. For the study of insulin action, 16 h-
fasted mice (16 weeks old) were injected with 2 U/kg insulin intra-
peritoneally and tissues collected after 10 min and snap frozen.
Glucose tolerance testing was performed on overnight (16 h) fasted
mice using 2 g/kg 20% glucose via oral gavage. Insulin tolerance
testing was done by giving 0.5 U/kg intraperitoneal insulin to 6 h-
fasted mice. For lipid tolerance testing, 16 h-fasted mice were
administered 10 mL/kg olive oil by gavage.
Hyperinsulinemic euglycemic clamp studies and subsequent sample
processing and analysis were conducted as described previously [21]
on 16 week old mice after overnight fasting. The clamps used a
priming dose of human insulin (0.7 mU), followed by constant insulin
and [3-3H]-D-glucose infusion at 7 mU/h and 0.72 mCi/h, respectively.
2.4. Study of tissue insulin responsiveness ex vivo
Measurement of insulin action on isolated Soleus and Extensor Dig-
itorum Longus was undertaken in 16-week-old male mice as
described [22]. For primary preadipocyte differentiation studies, fat
pads from 8 week-old male mice were isolated and cultured as
described [20], but without 5-Triiodo-L-thyronine.
2.5. Biochemical assays
Blood was collected by cardiac puncture and plasma snap frozen
before assays detailed in Supplemental Table 3. Glycogen hydrolysis in
1 M HCl (2.5 h at 100 C), NaOH neutralization and fluorometric
glucose analysis were used to determine the glycogen content of snap-
frozen liver [23]. Hepatic triglyceride determination was used in the
Triglyceride Colorimetric Assay kit (Cayman). Hepatic cholesterol was
extracted from 10 mg of liver using a 400 mL
chloroform:isopropanol:NP-40 mixture (7:11:0.1) before centrifuga-
tion, 30 min vacuum drying (50 C) and dissolving in phosphate-
buffered saline (PBS). The samples were assayed by Siemens
Healthcare Diagnostics kit.
2.6. Metabolomic studies
Liver metabolites were extracted from tissue snap-frozen after
dissection using a reported methanol/chloroform method [24].
Aqueous metabolites were further extracted as described in [24] and
analysed using a Vanquish ultra-high performance liquid chromatog-
raphy (UHPLC) system and TSQ Quantiva triple quadrupole mass
spectrometer (Thermo Scientific) with compounds directly infused.
Parameter optimisation used 1 mM standard solutions in a chro-
matographic buffer. Optimal mass spectrometry parameters and mass
transitions were generated by automatic MassLynx (Version 1.4,
Waters) protocols or, if standards were unavailable, deduced from
known analogue parameters.MOLECULAR METABOLISM 40 (2020) 101020
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2.7. Assessment of de novo lipogenesis
Sixteen week chow-fed mice were fasted overnight, injected intra-
peritoneally with deuterated saline (24 mL/g), and given high carbo-
hydrate diet (Harlan Teklad Diets, Cat no. TD88232) and 4%
deuterated water (Goss Scientific Instruments Ltd, Cat no. DLM-2259)
from 1 to 24 h later. Subsequent to culling, livers were snap-frozen and
50 mg homogenised in 600 mL methanolechloroform (2:1) before
extraction and analysis as described [25].
2.8. Histology
The sizes of at least 1000 adipocytes per genotype from 16-week-old
chow-fed mice were measured in Formalin-fixed, paraffin-embedded
(FFPE) tissue as described [26]. Adipose Treg cells were isolated and
counted by FACS, also as reported [27].
2.9. Gene expression analysis
For protein studies fresh tissues were snap-frozen in liquid nitrogen,
and homogenised using MD ceramic beads in RIPA buffer with pro-
teinase/phosphatase inhibitors (liver, muscle) (Roche) or mortar and
pestle in liquid nitrogen before dissolving in buffer (adipose). Protein
concentrations were determined by BCA assay (BioRad). Western
blotting employed the Novex gel system (Thermo Fisher Scientific).
Antibodies are shown in Supplemental Table S4. Quantification
employed the BioRad image system.
Total RNA was extracted and reverse transcribed for qPCR as previ-
ously described [28]. Target expression was normalised to the geo-
metric mean of 4 housekeeping genes (Ywhaz, Ppia, B2m and Eef1a1)
(Supplemental Table S4 for primer/probe sequences). RNA sequencing
protocols and analysis have previously been reported [29].
2.10. Statistical analysis
D’Agostino & Pearson or ShapiroeWilk tests were performed to test for
Gaussian distribution of data. For Gaussian data, unpaired two-tailed
Student’s t tests for two group comparison and ANOVA with post
hoc for multiple group comparison were performed using GraphPad
Prism (GraphPad Software). For non-Gaussian data ManneWhitney
testing was used for two group comparison and KruskaleWallis and
Dunn’s multiple comparison testing were used for multiple group
analysis using GraphPad Prism (GraphPad Software). Tissue weights,
food consumption and energy expenditure were analysed by ANCOVA
using XLSTAT (Addinsoft).
2.11. Data and resource availability
All transcriptomic data were deposited in GEO under accession number
GSE153431. Other datasets, and the Pik3r1WT/Y657* mice generated
during the current study are available from the corresponding author
upon reasonable request.
3. RESULTS
3.1. Growth and development of Pik3r1 Y657* knock-in mice
Mice harbouring the Pik3r1 Y657* mutation were generated by
homologous recombination-based gene targeting (Figure S1A).
Immunoblotting confirmed the expression of truncated p85a at
greater amounts than full length protein in most tissues, likely due to
the loss of an ubiquitylation motif located beyond the nonsense
mutation in the C-terminal [30]. No compensatory change in PI3K
p85b subunit was seen. p110a subunit expression was reduced in
subcutaneous white adipose tissue, and p110b expression was
reduced in liver, subcutaneous and epididymal white adipose tissue
(Figure S1B).MOLECULAR METABOLISM 40 (2020) 101020  2020 The Authors. Published by Elsevier GmbH. This is
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they were smaller, with poorly developed limb buds and reduced eye
pigmentation. Heterozygous embryos were smaller from E15.5
(Figure S2AeE). Pik3r1WT/Y657* mice were born at the expected fre-
quency, but showed impaired linear growth and body weight on chow
(Figure 1AeC). At 16 weeks, there was a small decrease in whole body
adiposity (Figure 1D), however, no difference was found in epididymal
or inguinal white adipose nor interscapular brown adipose depot
weights when lean mass was taken into account (Figure 1EeG).
Plasma leptin concentrations were similar in male Pik3r1WT/Y657* and
wild-type mice (3.3 1.2 vs 2.6 0.3 mg/L on fasting (n¼ 9,10; NS);
10.3 2.2 vs 15.9 3.9 mg/L on ad libitum feeding (n¼ 13,13; NS)).
Liver weights were indistinguishable (Figure 1H), but hearts were
heavier in Pik3r1WT/Y657* mice (Figure 1I). No difference in food con-
sumption nor energy expenditure was seen at 16 weeks on chow
(Figure 1J,K), however, the respiratory exchange ratio (RER) was
higher during the light phase in Pik3r1WT/Y657* mice, blunting the
circadian fluctuation (Figure 1L). Similar differences were seen be-
tween heterozygous and wild-type females for all variables assessed in
both sexes.
3.2. Response of Pik3r1WT/Y657* mice to a high-fat diet
To assess whether placing a greater load on adipose tissue in
Pik3r1WT/Y657* mice would unmask lipodystrophy, mice were fed a
45% fat diet (HFD) from 8 weeks old. Pik3r1WT =Y 657
*
mice showed
reduced weight gain and body fat over the 8 weeks of study
(Figure 2A,B). Epididymal white adipose tissue was most severely
affected (Figure 2C), with no significant difference in inguinal nor
brown adipose tissue (Figure 2D,E). Lean mass did not increase at a
greater rate in Pik3r1WT/Y657* mice (Figure S3A,B), and liver weights
also did not differ, while heart weights were elevated in
heterozygotes, as on chow (Figure 2F,G). Consistent with reduced
adiposity, Pik3r1WT/Y657* mice had lower serum leptin concentrations
when fed (37.7 7.3 vs 11.3 2.0 mg/L (n¼ 15,11; p¼ 3 103)),
but not when fasted (15.9  3.9 vs 10.3  2.2 mg/L (n ¼ 13,13; not
significant)), while adiponectin concentrations were unchanged
(Table 1).
Given reduced adipose expansion, we subsequently sought histological
evidence of “adipose failure”, namely adipocyte hypertrophy and
inflammation, which would be expected in lipodystrophy when adipose
expansion is pathologically constrained, causing adipose injury on
positive energy balance. The histological appearance and adipocyte
size distribution in epididymal adipose tissue was indistinguishable
between genotypes (Figure 2H,I), however with no evidence of
inflammation, nor fibrosis. Consistent with the lack of histological
evidence of adipose overload, ex vivo differentiation of preadipocytes
from inguinal or epididymal depots was unaltered (Figure 2J). Finally,
given the role of Pik3r1 in lymphocyte function, and the important role
of adipose-resident T regulatory (Treg) cells in energy homeostasis, the
adipose content of Treg cells was assessed by FACS. No major dif-
ference was observed between genotypes (Figure 2K).
Given these findings, which are at odds with a true lipodystrophy, we
then assessed whether reduced adipose accretion rather reflected
altered energy homeostasis. Pik3r1WT/Y657* mice exhibited increased
food intake (Figure 2L) and energy expenditure (Figure 2M) when the
size of the animals was taken into account, but locomotor activity was
unchanged across 24 h (Figure 2N). Markedly reduced accumulation of
adipose tissue despite increased food intake, and without sustained
hyperglycaemia, demonstrates severely reduced food efficiency. This
indicates that increased food intake is a compensatory response to
chronically increased energy expenditure rather than a primaryan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 3
Figure 1: Effect of Pik3r1 Y657* on prenatal development and postnatal growth. (A) Representative image of Pik3r1WT/WT (WT/WT) and Pik3r1WT/Y657* (WT/Y657*) mice at 18
weeks old. (B) Body lengths (nose to anus) at 18 weeks of Pik3r1WT/WT and Pik3r1WT/Y657* mice (n ¼ 11 and 18 respectively). (C) Bodyweight increase from 8 to 16 weeks of
Pik3r1WT/WT and Pik3r1WT/Y657* (n ¼ 16 and 12 respectively). (D) The relationship between lean and fat mass of Pik3r1WT/WT and Pik3r1WT/Y657* mice (n ¼ 16 and 12 respectively).
Masses of (E) inguinal adipose tissue (IngWAT) (F) Epididymal adipose tissue (eWAT), (G) Brown adipose tissue (BAT), (H) Liver, and (I) Heart of Pik3r1WT/WT and Pik3r1WT/Y657* mice
(n ¼ 11 and 7 respectively). (J) Food intake (n ¼ 13 for Pik3r1WT/WT and n ¼ 14 for Pik3r1WT/Y657*), (K) Energy expenditure and (L) Respiratory exchange ratio (RER) (n ¼ 7 for
Pik3r1WT/WT and n ¼ 13 for Pik3r1WT/Y657*) of wild-type and heterozygous mice assessed at 18 weeks old. All data shown are from male mice. Masses and energy expenditure are
shown relative to total lean mass, and were analysed statistically by ANCOVA. * ¼ p < 0.05; *** ¼ p < 0.001; **** ¼ p < 0.0001. Mean  SD are shown for plots in (B), (C)
and (L).
Original Articlephenomenon. As on chow, the circadian RER profile was blunted, with
higher values in the dark phase and no discernible difference between
light and dark phases for Pik3r1WT/Y657* mice (Figure 2O), suggesting
greater carbohydrate oxidation in the dark phase.
3.3. Pik3r1WT/Y657* mice are severely insulin resistant
At 12 weeks old, neither male nor female Pik3r1WT/Y657* mice on chow
were hyperglycaemic compared to controls, but plasma insulin con-
centrations were raised, more severely on feeding (Tables 1 and S1).4
 2020 The Authors. Published by Elsevier GOn high-fat feeding, male Pik3r1WT/Y657* mice remained hyper-
insulinemia, but the difference between mutant and control mice was
abolished by the greater increase in insulin concentrations in wild-type
mice. Blood glucose concentration was paradoxically lower in fed
Pik3r1WT/Y657* mice on HFD. Plasma adiponectin concentrations in
fasted chow-fed Pik3r1WT/Y657* mice were lower than in wild-type
controls, however no significant difference was seen in other condi-
tions, despite the severe IR of heterozygous mice (Table 1). In
Pik3r1WT/Y657* mice on HFD, adiponectin normalised to body fat wasMOLECULAR METABOLISM 40 (2020) 101020
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 2: Response of Pik3r1WT/Y657* mice to a palatable 45% fat diet. (A) Bodyweight increase from 8 to 16 weeks of Pik3r1WT/WT (WT/WT) and Pik3r1WT/Y657* (WT/Y657*)
(n ¼ 16 and 12 respectively). (B) The relationship between lean and fat mass of Pik3r1WT/WT and Pik3r1WT/Y657* mice (n ¼ 16 and 12 respectively). Masses of (C) Epididymal
adipose tissue (eWAT), (D) Inguinal adipose tissue (IngWAT), (E) Brown adipose tissue (BAT), (F) Liver, and (G) Heart of Pik3r1WT/WT and Pik3r1WT/Y657* mice (n ¼ 12 for both
genotypes). (H) Representative histological appearance of haematoxylin and eosin-stained eWAT from Pik3r1WT/WT and Pik3r1WT/Y657* mice. Scale bars ¼ 100 mm (I) Adipocyte size
distribution in eWAT based on quantification of >1000 cells per genotype from 4 wild-type and 4 heterozygous mice. The inset shows a zoomed-in view of the percentage of cells
smaller than 10 000 mm2. (J) Representative images of ex vivo differentiated stromal vascular cells from ingWAT stained with Oil Red O. (K) Percentage of CD4þ and regulatory T
cells in the eWAT (n ¼ 3 for Pik3r1WT/WT and n ¼ 3 for Pik3r1WT/Y657*). (L) Food intake (n ¼ 13 for Pik3r1WT/WT and n ¼ 14 for Pik3r1WT/Y657*) and (M) Energy expenditure (n ¼ 17
for Pik3r1WT/WT and n ¼ 10 for Pik3r1WT/Y657*) of wild-type and heterozygous mice assessed at 18 weeks old. All masses and energy expenditure are shown relative to total lean
mass, and were analysed statistically by ANCOVA. (N) Locomotor activity of Pik3r1WT/WT and Pik3r1WT/Y657* mice (n ¼ 17 and n ¼ 10 respectively). (O) Respiratory exchange ratio
(RER) (n ¼ 17 for Pik3r1WT/WT and n ¼ 10 for Pik3r1WT/Y657*) of wild-type and heterozygous mice assessed at 18 weeks old. All data shown are from male mice. Mean  SD are
shown. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
MOLECULAR METABOLISM 40 (2020) 101020  2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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 2020 The Authors. Published by Elsevier Ghigher than in controls, reminiscent of the preserved adiponectin seen
in severely insulin-resistant patients with SHORT syndrome [7]. Nor-
malised plasma leptin concentrations, in contrast, were lower
(Figure S3C,D).
Hyperinsulinemic euglycemic clamps were undertaken on chow- and
HFD-fed male mice. Chow-fed Pik3r1WT/Y657* mice required a steady
state glucose infusion rate of only one eighth that required by wild-type
mice, confirming severe IR (Figure 3A). On HFD, Pik3r1WT/Y657* mice
remained extremely insulin resistant, however the difference between
genotypes was much smaller than on chow due to increased IR in wild-
type animals (Figure 3A). Further studies were thus carried out on
chow. Glucose and insulin excursions on oral glucose tolerance testing
showed a trend towards an increase in male Pik3r1WT/Y657* mice
(Figure 3B,C), but were increased in female mice (Figure S4A,B), while
the hypoglycaemic response to insulin was attenuated in both sexes
(Figures 3D and S4C). Clamp studies in males using isotopic tracers
showed glucose disposal to be 19% lower in Pik3r1WT/Y657* mice
(Figure 3E) while suppression of hepatic glucose production by
hyperinsulinemia was 49% lower compared to wild type littermates
(Figure 3F). Liver glycogen content was similar between genotypes
(Figure 3G). Insulin infusion lowered plasma free fatty acid concen-
trations in wild-type mice, but little suppression was seen in hetero-
zygous mice, consistent with impaired suppression of adipose lipolysis
(Figure 3H).
Intraperitoneal insulin in male mice strongly induced Akt phosphory-
lation in the liver, skeletal muscle and epididymal and inguinal adipose
tissue of wild-type controls, as expected, and this was reduced in
Pik3r1WT/Y657* mice (Figures 3IeL and S5AeD). As muscle insulin
sensitivity was previously reported not to be reduced in Pik3r1WT/R649W
mice [31], insulin responsiveness of soleus and extensor digitorum
longus (EDL) muscles was assessed ex vivo. Soleus and EDL muscle
from Pik3r1WT/Y657* mice both showed a 1.3-fold reduction in insulin-
stimulated deoxyglucose uptake compared to wild-type muscle
(Figure 3M). Insulin-induced Akt phosphorylation was also markedly
reduced in both types of muscle ex vivo to a much more significant
degree than in vivo (Figures 3N,O and S5E). This finding of muscle
insulin resistance using several techniques, although contrasting with
clamp studies reported previously, is consistent with the robust
expression of Pik3r1 gene products in skeletal muscle.
3.4. Pik3r1WT/Y657* mice are hypolipidemic
Having demonstrated that, as in SHORT syndrome, heterozygous
Pik3r1WT/Y657* mice show severe IR and reduced adiposity, we
assessed whether, like humans, they do not exhibit fatty liver nor
metabolic dyslipidaemia. In fed and fasting states, on either chow or
HFDs, Pik3r1WT/Y657* mice showed hypolipidemia, with lower plasma
total cholesterol and HDL cholesterol (Table 1). This was most striking
in fed mice on HFD, mirroring the lower glucose seen in Pik3r1WT/Y657*
mice in this state. Plasma triglyceride concentrations were also lower
in heterozygous animals in all states except when the fasting state
after HFD. Plasma free fatty acid concentrations were lower in all
states except in fed animals maintained on chow. Similar hypo-
lipidemia was seen in chow-fed female mice on fasting (Table S1). No
difference was seen in VLDL concentrations in chow- or high fat-fed
mice (Table 1).
Despite severe IR in Pik3r1WT/Y657*mice, no difference was seen in liver
triglyceride content compared to controls either on chow or HFD,
assessed by Oil-Red-O staining and biochemical quantification
(Figure 4A,B). Liver cholesterol content was also the same in chow-fed
animals of both genotypes (Figure 4C). Oral lipid tolerance testing
revealed similar triglyceride excursion after lipid loading in bothMOLECULAR METABOLISM 40 (2020) 101020
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Figure 3: Pik3r1WT/Y657* mice show systemic and tissue-level insulin resistance. (A) Glucose infusion rates during hyperinsulinemic euglycemic clamping of Pik3r1WT/WT (WT/
WT) and Pik3r1WT/Y657* (WT/Y657*) mice on chow (n ¼ 4 and 4) or 45% fat diet (n ¼ 10 and 11) at 16 weeks old. (B) Oral glucose tolerance test (OGTT) and corresponding
comparison of areas under the curves (AUC) of Pik3r1WT/WT and Pik3r1WT/Y657* mice on chow at 12 weeks old (n ¼ 10 and 9). (C) Insulin concentrations and AUC for the same
OGTT as in (B). (D) Insulin tolerance test and AUC comparison for the same mice 1 week later. (E) Glucose disposal and (F) suppression of hepatic glucose output by insulin during
hyperinsulinemic euglycemic clamping of Pik3r1WT/WT and Pik3r1WT/Y657* mice on chow at 18 weeks old (both n ¼ 4). (G) Glycogen content of livers during a fastingerefeeding
cycle in chow fed animals at 16 weeks old (both n ¼ 6). (H) Plasma non-esterified free fatty acid concentrations during hyperinsulinemic euglycemic clamping (both genotypes
n ¼ 4). (I)e(L) Representative images of immunoblots and corresponding quantifications of tissue lysates from mice injected intraperitoneally with 2 U/kg insulin 10 min prior to
sacrifice, showing pAktSer473, total Akt and their ratio: (I) Liver, (J) Skeletal muscle (K) eWAT, (L) ingWAT (n ¼ 6 per genotype and condition). (M) Insulin-induced fold increase of
glucose uptake into ex vivo incubated soleus (n ¼ 18 for Pik3r1WT/WT, n ¼ 11 for Pik3r1WT/Y657*) and Extensor Digitorum Longus (EDL) (n ¼ 20 and 11). (N) Representative
immunoblots of Soleus and EDL lysates from the same paradigm as in (M). (O) Quantification of pAktSer473 to total Akt ratios from soleus and EDL immunoblots (n ¼ 5 and 4 for
both). Data are from male mice. Quantitative data are presented as mean  SD. * ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001 and **** ¼ p < 0.0001.genotypes (Figure 4D), and bomb calorimetry of faeces on chow
showed the same energy content (Figure 4E), excluding abnormal in-
testinal lipid handling as the explanation for hypolipidemia and reduced
adiposity.MOLECULAR METABOLISM 40 (2020) 101020  2020 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comInsulin stimulates hepatic de novo lipogenesis and cholesterogenesis
via Srebp1 and Srebp2 respectively. In prevalent IR, hepatic de novo
lipogenesis is enhanced, and the mismatch between this and the
reduced hypoglycaemic action of insulin is evidence for “partial IR” inan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 7
Figure 4: Lipid handling and liver phenotype of Pik3r1WT/Y657* mice. (A) Representative images of Oil-Red-O-stained livers of chow-fed and 45% fat diet-fed Pik3r1WT/WT (WT/
WT) and Pik3r1WT/Y657* (WT/Y657*) mice. Scale bars ¼ 200 mm. (B) Hepatic triglyceride and (C) Hepatic total cholesterol concentration during a fasting refeeding cycle of chow fed
mice at 16 weeks old (n ¼ 6 per genotype). (D) Lipid tolerance testing and comparison of areas under the curve (AUC), also of chow-fed mice, at 16 weeks old. Triglyceride
concentrations were equalised at baseline by matching the difference between genotypes with the lower values of heterozygous mice, and the same fixed correction was applied to
all points on the graph (n ¼ 11 and n ¼ 17 for wild-type and heterozygous mice respectively). (E) Faecal energy content determined by bomb calorimetry of chow fed mice at 16
weeks old (n ¼ 8 and 8). (F) De novo palmitate measured by stable deuterium enrichment (n ¼ 7 and n ¼ 10 for wild-type and heterozygous mice respectively). (G)e(M) Liver
mRNA expression, determined by quantitative real time PCR of (G) Srebp1 and its transcriptional targets (H) Acc1, (I) Fasn, and (J) Scd1, and of (K) Srebp2 and its transcriptional
targets (L) Mvk and (M) Nsdhl in chow fed mice during a fasting refeeding cycle at 16 weeks old (n ¼ 6 per genotype per condition). All data shown are from male mice. Numerical
data are presented as mean  SD.
Original Articlemetabolic dyslipidaemia [19]. Liver PI3K mediates the action of insulin
on lipogenesis, with hypolipidemia despite IR seen in numerous
models in which hepatic insulin/Irs/PI3K/Akt2/mTORC2 signalling is
impaired [14e16,18,32]. Based on these findings, we hypothesised
that the hypolipidemia seen in Pik3r1WT/Y657* mice would be
accounted for by reduced hepatic de novo lipogenesis, as in SHORT
syndrome due to PIK3R1 Y657* [7]. In keeping with this, no increased
de novo synthesis of palmitate could be measured in heterozygotes
despite fasting hyperinsulinemia and refeeding with a high carbohy-
drate diet (Figure 4F). Liver mRNA expression of Srebp1c, Srebp2 and8
 2020 The Authors. Published by Elsevier Gkey target genes (Acc1, Fasn, Scd1 and Mvk, Nsdhl, respectively) was
also determined in chow-fed animals in fed, fasting and refed states,
and no difference was seen in the expression of any of these genes
under any nutritional conditions (Figure 4GeM).
Other transcriptional regulators relevant to hypolipidemia include
carbohydrate response element binding protein (Chrebp) and Xbp1,
with the latter binding p85a and facilitating its nuclear translocation
[31,33,34]. A sentinel Chrebp-responsive gene (Pklr) showed mild but
significant reduction of mRNA in the fasting state, but mRNA of two
Xbp1 target genes (Acacb and Dgat2) showed no reduction during aMOLECULAR METABOLISM 40 (2020) 101020
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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fasting refeeding cycle (Figure S6AeC). It has also been proposed that
modulation of the ratio between Glucose-6-phosphatase (G6pc) and
Glucokinase (Gck) toggles hepatocyte glucose flux between lipogen-
esis and glucose production, and that this operates before transcrip-
tional changes in lipogenic transcription factors [35]. However,
although an increase in G6pc:Gck liver transcript levels was seen on
fasting of wild-type mice, the ratio was suppressed in Pik3r1WT/Y657*
mice, as reported in mice on Western-type diet [35] (Figure S6DeF).
We conclude that the consistent hypolipidemia seen in Pik3r1WT/Y657*
mice does not correlate with reduced insulin-induced lipogenesis in
the liver, suggesting that the reduced blood lipid concentrations are not
explained by attenuation of insulin’s lipogenic actions.
Given the lack of transcriptional perturbation of known lipogenic fac-
tors, global liver transcriptomic analysis was performed in fed and 16 h
fasted states. Genotypes were compared in each state, and fasting
gene expression was compared to fed gene expression for both ge-
notypes. Gene-based analysis confirmed prior findings, but provided
no obvious alternative explanation for hypolipidemia. Pathway analysis
of predicted upstream regulators showed modest but significant dif-
ferences in the fed state, with a transcriptional signature of reduced
Endoplasmic Reticulum (ER) stress (upstream regulators Xbp1, its
processing enzyme Ern1 (Ire1), and Atf6), and altered signatures of
several cytokines including IL6 (reduced), IL21, interferons gamma and
alpha 2 (increased) (Figure 5, Table S2). More significant differences
were seen after 16-h fasting, when a transcriptional profile consistentFigure 5: Pathway analysis of liver transcriptomes of fed and fasted mice. Volcano
Analysis (IPA) of transcriptomes of fed and fasted male Pik3r1WT/Y657* (n ¼ 6,6) mice and
in the fasting state compared to the fed state for wild-type (WT; left) and Pik3r1WT/Y657* (rig
mice in the fed state (top) and fasting state (bottom). The green dots represent data point w
differential activity in either genotype-based comparison are coloured red (activation z score
vs WT mice) in the outside plots showing differences based on nutritional state. Statistica
MOLECULAR METABOLISM 40 (2020) 101020  2020 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.comwith the reduced activity of Rictor, the defining component of mTORC2,
was seen with high significance, while patterns associated with Myc
and Mycn were upregulated. The large preponderance of changes
observed between fed and fasting states in wild-type mice, including
strong upregulation of PPARa-responsive genes, was however
conserved in heterozygous animals (Figure 5, Table S2).
In view of the transcriptomic evidence of reduced Rictor activity,
plasma and hepatic amino acid and b-hydroxybutyrate concentrations
were determined. This revealed increased b-hydroxybutyrate in the
liver from fed Pik3r1WT/Y657* mice with a trend towards an increase in
plasma, but no difference between genotypes when fasted
(Figure S7A). The fall in plasma amino acid concentrations seen in
fasting wild-type mice was lost in Pik3r1WT/Y657* mice, with a trend
towards a generalised increase in liver amino acids (Figure S7B,C).
These findings add to the evidence for abnormal transitions between
fed and fasted states in Pik3r1WT/Y657* mice, and suggest that reduced
intra-hepatocyte amino acid concentrations on fasting do not explain
the pronounced reduction in Rictor signalling suggested by
transcriptomics.
4. DISCUSSION
Most monogenic defects causing severe IR primarily affect adipose
tissue development, and metabolically phenocopy common IR [1]. In
contrast, humans with severe IR due to proximal insulin signallingplots are shown for predicted upstream regulators derived from Ingenuity Pathway
wild-type littermates (n ¼ 6,6). Outside plots show regulators showing differential activity
ht) mice. Central plots show regulators with differential activity in Pik3r1WT/Y657* vs WT
ith an activation z score <2 or >þ2 and a p-value <1  105. Regulators showing
> þ2 in Pik3r1WT/Y657* vs WT mice) or blue (activation z score < 2 in Pik3r1WT/Y657*
l analysis was performed using a general linear model with Bonferroni correction.
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plasma adiponectin concentration usual in common IR [6,7,13,36].
This was first noted in people with insulin receptor mutations [13], but
more recently, has been described in SHORT syndrome [6,7], in which
the lack of fatty liver and dyslipidaemia is particularly striking given
concomitant lipodystrophy. Fatty liver and atherogenic dyslipidaemia
are major sources of IR-related morbidity, so investigating how these
are dissociated from IR in the face of proximal insulin signalling defects
will potentially reveal novel approaches to mitigate IR-associated
disease.
The novel mice generated, heterozygous for the Pik3r1 Y657* allele,
show reduced growth, severe IR, and severely reduced adipose ac-
cretion on high-fat feeding. Although IR in Pik3r1R649W/WT mice
described previously was reported to spare skeletal muscle [31], we
found skeletal muscle to be insulin resistant both in clamps, and
ex vivo, in keeping with the ubiquitous expression of the mutant allele.
Despite severe IR, Pik3r1WT/Y657* mice were hypolipidemic on chow or
HFD, and in fed and fasted states, while the increase in liver triglyc-
eride usual in lipodystrophic IR was absent, validating it as a model of
the human phenomenon we aimed to study. Knockout evidence that
PI3K signalling mediates insulin’s stimulation of liver de novo lipo-
genesis led us to expect reduced transcript levels of Srebp and its
target genes (e.g. [16,17]), however we found no evidence supporting
this or other candidate transcriptional mechanisms including reduced
lipogenic activity of Xbp1 [34].
RNA sequencing showed most insulin-responsive genes to respond
normally to fasting and refeeding. Given elevated plasma insulin
concentrations, this could be construed as showing compensated
hepatic IR, as expected from a proximal insulin signalling defect.
Fasting-responsive programmes, such as those orchestrated by
PPARa, were intact in Pik3r1WT/Y657* mice, however pathway analysis
suggested reduced ER stress signalling and showed altered inflam-
matory signatures in the fed state, with a strikingly reduced Rictor
signature in the fasted state. These transcriptional clues may be
pertinent to the protection from dyslipidaemia as ER stress signalling
promotes fatty liver and dyslipidaemia [37], while Rictor drives hepatic
lipogenesis [38], however further study is needed. Impaired induction
of Rictor activity in this case may reflect Pik3r1’s role in amino acid
activation of Rictor [39].
Pik3r1R649W/WT mice have been shown to have less subcutaneous
adipose tissue [31] and reduced adipose expansion in obesogenic
conditions [40], as in the current report, which was interpreted as
evidence of lipodystrophy. However, constrained adipose expansion
produces inflammation of overloaded, hypertrophic adipose tissue
during chronic positive energy balance [1], and the normal adipocyte
appearance, lack of adipose inflammation, and normal differentiation
of preadipocytes ex vivo in both studies argue against this [31].
Reduced adipose mass can reflect altered energy balance rather than
lipodystrophy. Reduction of PI3K pathway activity by overexpression of
the lipid phosphatase Pten in mice was previously reported to enhance
energy expenditure via brown adipose tissue activation [41], albeit
without IR, while pharmacological or genetic inhibition of the p110a
catalytic subunit of PI3K has also been associated with increased
energy expenditure [40e43]. Moreover, a similar energetic phenotype
on brown adipose-specific knockout of Pik3r1 has recently been
described [44]. On HFD we found that food intake and energy
expenditure were both increased in Pik3r1WT/Y657* mice. Given unal-
tered locomotor activity, intestinal lipid absorption, and lean tissue
growth, reduced adipose accumulation shows that increased energy
expenditure outweighed increased food intake, and is thus the primary10
 2020 The Authors. Published by Elsevier Gabnormality. Reduced thermal insulation in smaller animals is an un-
likely explanation [43]; hence, we conclude that increased energy
expenditure explains reduced adipose accretion. Increased brown
adipose tissue activity is the most likely explanation, as in models with
p110a inhibition [40e43], but this requires further study.
Increasing brown adipose tissue function reduces plasma triglyceride
and cholesterol concentrations [45,46], and this reduces atherogen-
esis when liver scavenging of triglyceride-depleted lipoproteins is
intact [45]. This accords with the hypolipidemia of Pik3r1WT/Y657*
mice, and humans with SHORT syndrome. As brown fat is now known
to occur in humans, it would be of interest to establish whether it is
hyperactive in people with SHORT syndrome. In addition, given the
normal lipid profile despite severe IR in people with insulin receptor
mutations [13], and the reduced adipose tissue in mice harbouring a
common dominant negative insulin receptor allele on an obesogenic
diet [47], it will be of interest to assess whether the bioenergetic
consequences of reduced PI3K signalling are also seen in the face of
insulin receptor dysfunction.
5. CONCLUSIONS
We report a novel mouse model of SHORT syndrome recapitulating the
severe IR without dyslipidaemia seen in humans. Hepatic lipogenesis
and lipogenic gene expression were unimpaired, and transcriptomic
pathway analysis suggested only mild nutritional state-specific ab-
normalities in liver gene expression. White adipose tissue was reduced
on HFD, but did not show inflammation of hypertrophy, while energy
expenditure was increased, raising the testable possibility that the
reduced adipose mass in SHORT syndrome does not represent true
“lipodystrophy”. The most likely mechanism explaining uncoupling of
IR from dyslipidaemia in SHORT syndrome is increased brown adipose
activity, consistent with other murine evidence that inhibition of PI3K
results in beneficial metabolic alterations as well as IR.
AUTHOR CONTRIBUTIONS
Conceptualization, RKS, AK; Methodology, SV, AK, PV, IZ, JJ, JG, JW,
RA Formal Analysis, AK, IZ, SV, IHD, PT, DAB, DH, RK, PV, JG, JW, JJ,
RKS; Investigation, AK, IZ, SV, IL, IHD, PT, DAB, DH, RK, PV, JJ, RKS;
Writing e Original Draft, RKS, AK, IHD; Writing e Review & Editing, IZ,
SV, PT, DAB, DH, RK, AVP, PV, JJ, SO; Supervision, RKS; Project
Administration, RKS; Funding Acquisition, RKS, SO, AVP.
ACKNOWLEDGEMENTS
RKS is the guarantor of this work, had full access to study data and takes re-
sponsibility for data integrity and accuracy of data analysis. The authors have
declared that no conflict of interest exists. Parts of this work have been presented at
scientific conferences (Keystone symposium, January 2018) and a previous version
of the manuscript was deposited at bioRxiv (224485). RKS and SO were supported by
the Wellcome Trust [grants 210752/Z/18/Z and WT095515 respectively], and by the
Medical Research Council (MRC) [grant MC_UU_12012/5]. AVP and SV were funded
by the British Heart Foundation [grant RG/18/7/33636] and the MRC
[MC_UU_12012/2]. Animal work was conducted in the MRC Disease Model Core
[MC_UU_12012/5]. We are grateful for technical assistance from Amy Warner at the
MRC Disease Model Core, Keith Burling at the MRC MDU Mouse Biochemistry
Laboratory, James Warner at the Histology Core Facility and Davide Chiarugi, Brian
Lam and Marcella Ma at the IMS-BIO2 Core Facility, all funded by the MRC
(MRC_MC_UU_12012/5). We thank Gregory Strachan at the Imaging Core Facility,
funded by the Wellcome Trust [Grant 100574/Z/12/Z].MOLECULAR METABOLISM 40 (2020) 101020
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
CONFLICT OF INTEREST
The authors declare no conflicts of interest.
APPENDIX A. SUPPLEMENTARY DATA
Supplementary data to this article can be found online at https://doi.org/10.1016/j.
molmet.2020.101020.
REFERENCES
[1] Mann, J.P., Savage, D.B., 2019. What lipodystrophies teach us about the
metabolic syndrome. Journal of Clinical Investigation 130. https://doi.org/
10.1172/jci129190.
[2] Leiter, S.M., Semple, R.K., 2017. Insulin resistance and diabetes associated
with lipodystrophies. In: Diabetes associated with single gene defects and
chromosomal abnormalities, vol. 25. p. 119e33.
[3] Chudasama, K.K., Winnay, J., Johansson, S., Claudi, T., König, R.,
Haldorsen, I., et al., 2013. SHORT syndrome with partial lipodystrophy due to
impaired phosphatidylinositol 3 kinase signaling. American Journal of Human
Genetics 93(1):150e157. https://doi.org/10.1016/j.ajhg.2013.05.023.
[4] Dyment, D.A., Smith, A.C., Alcantara, D., Schwartzentruber, J.A., Basel-
Vanagaite, L., Curry, C.J., et al., 2013. Mutations in PIK3R1 cause SHORT
syndrome. American Journal of Human Genetics 93(1):158e166. https://
doi.org/10.1016/j.ajhg.2013.06.005.
[5] Thauvin-Robinet, C., Auclair, M., Duplomb, L., Caron-Debarle, M., Avila, M.,
St-Onge, J., et al., 2013. PIK3R1 mutations cause syndromic insulin resistance
with lipoatrophy. American Journal of Human Genetics 93(1):141e149.
https://doi.org/10.1016/j.ajhg.2013.05.019.
[6] Avila, M., Dyment, D.A., Sagen, J.V., St-Onge, J., Moog, U., Chung, B.H.Y.,
et al., 2016. Clinical reappraisal of SHORT syndrome with PIK3R1 mutations:
toward recommendation for molecular testing and management. Clinical Ge-
netics 89(4):501e506. https://doi.org/10.1111/cge.12688.
[7] Huang-Doran, I., Tomlinson, P., Payne, F., Gast, A., Sleigh, A., Bottomley, W.,
et al., 2016. Insulin resistance uncoupled from dyslipidemia due to C-terminal
PIK3R1 mutations. JCI Insight 1(17):e88766. https://doi.org/10.1172/
jci.insight.88766.
[8] Vanhaesebroeck, B., Stephens, L., Hawkins, P., 2012. PI3K signalling: the path
to discovery and understanding. Nature Reviews Molecular Cell Biology 13(3):
195e203. https://doi.org/10.1038/nrm3290.
[9] Cantley, L.C., 2002. The phosphoinositide 3-kinase pathway. Science
296(5573):1655e1657. https://doi.org/10.1126/science.296.5573.1655.
[10] Terauchi, Y., Tsuji, Y., Satoh, S., Minoura, H., Murakami, K., Okuno, a., et al.,
1999. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85
alpha subunit of phosphoinositide 3-kinase. Nature Genetics 21(2):230e235.
https://doi.org/10.1038/6023.
[11] Mauvais-Jarvis, F., Ueki, K., Fruman, D.A., Hirshman, M.F., Sakamoto, K.,
Goodyear, L.J., et al., 2002. Reduced expression of the murine p85alpha
subunit of phosphoinositide 3-kinase improves insulin signaling and amelio-
rates diabetes. Journal of Clinical Investigation 109(1):141e149. https://
doi.org/10.1172/JCI13305.
[12] Chen, D., Mauvais-Jarvis, F., Bluher, M., Fisher, S.J., Jozsi, A., Goodyear, L.J.,
et al., 2004. p50/p55 phosphoinositide 3-kinase knockout mice exhibit
enhanced insulin sensitivity. Molecular and Cellular Biology 24(1):320e329.
https://doi.org/10.1128/MCB.24.1.320-329.2004.
[13] Semple, R.K., Sleigh, A., Murgatroyd, P.R., Adams, C.A., Bluck, L.,
Jackson, S., et al., 2009. Postreceptor insulin resistance contributes to human
dyslipidemia and hepatic steatosis. Journal of Clinical Investigation 119(2):
315e322. https://doi.org/10.1172/JCI37432.MOLECULAR METABOLISM 40 (2020) 101020  2020 The Authors. Published by Elsevier GmbH. This is
www.molecularmetabolism.com[14] Biddinger, S.B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J.T.,
Alemán, J.O., Suzuki, R., et al., 2008. Hepatic insulin resistance is sufficient to
produce dyslipidemia and susceptibility to atherosclerosis. Cell Metabolism
7(2):125e134. https://doi.org/10.1016/j.cmet.2007.11.013.
[15] Kubota, N., Kubota, T., Itoh, S., Kumagai, H., Kozono, H., Takamoto, I., et al.,
2008. Dynamic functional relay between insulin receptor substrate 1 and 2 in
hepatic insulin signaling during fasting and feeding. Cell Metabolism 8(1):49e
64. https://doi.org/10.1016/j.cmet.2008.05.007.
[16] Taniguchi, C.M., Kondo, T., Sajan, M., Luo, J., Bronson, R., Asano, T., et al.,
2006. Divergent regulation of hepatic glucose and lipid metabolism by
phosphoinositide 3-kinase via Akt and PKCl/z. Cell Metabolism 3(5):343e353
https://doi.org/10.1016/j.cmet.2006.04.005.
[17] Sopasakis, V.R., Liu, P., Suzuki, R., Kondo, T., Winnay, J., Tran, T.T., et al.,
2010. Specific roles of the p110a isoform of phosphatidylinsositol 3-kinase in
hepatic insulin signaling and metabolic regulation. Cell Metabolism 11(3):
220e230. https://doi.org/10.1016/j.cmet.2010.02.002.
[18] Hagiwara, A., Cornu, M., Cybulski, N., Polak, P., Betz, C., Trapani, F., et al.,
2012. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt,
glucokinase, and SREBP1c. Cell Metabolism 15(5):725e738. https://doi.org/
10.1016/j.cmet.2012.03.015.
[19] Brown, M.S., Goldstein, J.L., 2008. Selective versus total insulin resistance: a
pathogenic paradox. Cell Metabolism, 95e96. https://doi.org/10.1016/
j.cmet.2007.12.009.
[20] Whittle, A.J., Jiang, M., Peirce, V., Relat, J., Virtue, S., Ebinuma, H., et al.,
2015. Soluble LR11/SorLA represses thermogenesis in adipose tissue and
correlates with BMI in humans. Nature Communications 6:8951. https://
doi.org/10.1038/ncomms9951.
[21] Schreiber, R., Hofer, P., Taschler, U., Voshol, P.J., Rechberger, G.N.,
Kotzbeck, P., et al., 2015. Hypophagia and metabolic adaptations in mice with
defective ATGL-mediated lipolysis cause resistance to HFD-induced obesity.
Proceedings of the National Academy of Sciences of the United States of
America 112(45):13850e13855. https://doi.org/10.1073/pnas.1516004112.
[22] Sell, H., Jensen, J., Eckel, J., 2012. Measurement of insulin sensitivity in
skeletal muscle in vitro. Methods in Molecular Biology 933:255e263. https://
doi.org/10.1007/978-1-62703-068-7.
[23] Lowry, O.H., Passonneaau, J.V., 1972. A flexible system of enzyme analysis.
Academic Press.
[24] Horscroft, J.A., Kotwica, A.O., Laner, V., West, J.A., Hennis, P.J.,
Levett, D.Z.H., et al., 2017. Metabolic basis to Sherpa altitude adaptation.
Proceedings of the National Academy of Sciences of the United States of
America 114(24):6382e6387. https://doi.org/10.1073/pnas.1700527114.
[25] Roberts, L.D., Virtue, S., Vidal-Puig, A., Nicholls, A.W., Griffin, J.L., Bethell, D.,
et al., 2009. Metabolic phenotyping of a model of adipocyte differentiation.
Physiological Genomics 39(2):109e119. https://doi.org/10.1152/
physiolgenomics.90365.2008.
[26] Virtue, S., Feldmann, H., Christian, M., Tan, C.Y., Masoodi, M., Dale, M., et al.,
2012. A new role for lipocalin prostaglandin D synthase in the regulation of
brown adipose tissue substrate utilization. Diabetes 61(12):3139e3147.
https://doi.org/10.2337/db12-0015.
[27] Mauro, C., Smith, J., Cucchi, D., Coe, D., Fu, H., Bonacina, F., et al., 2017.
Obesity-induced metabolic stress leads to biased effector memory CD4þ T
cell differentiation via PI3K p110d-Akt-mediated signals. Cell Metabolism
25(3):593e609. https://doi.org/10.1016/j.cmet.2017.01.008.
[28] Larder, R., Sim, M.F.M., Gulati, P., Antrobus, R., Tung, Y.C.L., Rimmington, D.,
et al., 2017. Obesity-associated gene TMEM18 has a role in the central control
of appetite and body weight regulation. Proceedings of the National Academy
of Sciences of the United States of America 114(35):9421e9426. https://
doi.org/10.1073/pnas.1707310114.
[29] Rocha, N., Bulger, D.A., Frontini, A., Titheradge, H., Gribsholt, S.B., Knox, R.,
et al., 2017. Human biallelic MFN2 mutations induce mitochondrialan open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 11
Original Articledysfunction, upper body adipose hyperplasia, and suppression of leptin
expression. ELife 6. https://doi.org/10.7554/elife.23813.
[30] Ko, H.R., Kim, C.K., Lee, S.B., Song, J., Lee, K.-H., Kim, K.K., et al., 2014. P42
Ebp1 regulates the proteasomal degradation of the p85 regulatory subunit of
PI3K by recruiting a chaperone-E3 ligase complex HSP70/CHIP. Cell Death &
Disease 5(3):e1131. https://doi.org/10.1038/cddis.2014.79.
[31] Winnay, J.N., Solheim, M.H., Dirice, E., Sakaguchi, M., Noh, H.L., Kang, H.J.,
et al., 2016. PI3-kinase mutation linked to insulin and growth factor resistance
in vivo. Journal of Clinical Investigation 126(4):1401e1412. https://doi.org/
10.1172/JCI84005.
[32] Leavens, K.F., Easton, R.M., Shulman, G.I., Previs, S.F., Birnbaum, M.J., 2009.
Akt2 is required for hepatic lipid accumulation in models of insulin resistance.
Cell Metabolism 10(5):405e418. https://doi.org/10.1016/j.cmet.2009.10.004.
[33] Park, S.W., Zhou, Y., Lee, J., Lu, A., Sun, C., Chung, J., et al., 2010. The
regulatory subunits of PI3K, p85a and p85b, interact with XBP-1 and increase
its nuclear translocation. Nature Medicine 16(4):429e437. https://doi.org/
10.1038/nm.2099.
[34] Lee, A.-H., Scapa, E.F., Cohen, D.E., Glimcher, L.H., 2008. Regulation of
hepatic lipogenesis by the transcription factor XBP1. Science 320(5882):
1492e1496. https://doi.org/10.1126/science.1158042.
[35] Haeusler, R.A., Hartil, K., Vaitheesvaran, B., Arrieta-Cruz, I., Knight, C.M.,
Cook, J.R., et al., 2014. Integrated control of hepatic lipogenesis versus
glucose production requires FoxO transcription factors. Nature Communica-
tions 5:5190. https://doi.org/10.1038/ncomms6190.
[36] Semple, R.K., Soos, M.A., Luan, J., Mitchell, C.S., Wilson, J.C., Gurnell, M.,
et al., 2006. Elevated plasma adiponectin in humans with genetically defective
insulin receptors. Journal of Clinical Endocrinology and Metabolism 91(8):
3219e3223. https://doi.org/10.1210/jc.2006-0166.
[37] Wang, L., Chen, J., Ning, C., Lei, D., Ren, J., 2018. Endoplasmic reticulum
stress related molecular mechanisms in nonalcoholic fatty liver disease
(NAFLD). Current Drug Targets 19. https://doi.org/10.2174/
1389450118666180516122517.
[38] Yuan, M., Pino, E., Wu, L., Kacergis, M., Soukas, A.A., 2012. Identification of
Akt-independent regulation of hepatic lipogenesis by mammalian target of
rapamycin (mTOR) complex 2. Journal of Biological Chemistry 287(35):
29579e29588. https://doi.org/10.1074/jbc.M112.386854.
[39] Tato, I., Bartrons, R., Ventura, F., Rosa, J.L., 2011. Amino acids activate
mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling.12
 2020 The Authors. Published by Elsevier GJournal of Biological Chemistry 286(8):6128e6142. https://doi.org/10.1074/
jbc.M110.166991.
[40] Solheim, M.H., Winnay, J.N., Batista, T.M., Molven, A., Njølstad, P.R.,
Kahn, C.R., 2018. Mice carrying a dominant-negative human PI 3-kinase
mutation are protected from obesity and hepatic steatosis but not diabetes.
Diabetes 67(7):db171509. https://doi.org/10.2337/db17-1509.
[41] Ortega-Molina, A., Efeyan, A., Lopez-Guadamillas, E., Muñoz-Martin, M.,
Gómez-López, G., Cañamero, M., et al., 2012. Pten positively regulates brown
adipose function, energy expenditure, and longevity. Cell Metabolism 15(3):
382e394. https://doi.org/10.1016/j.cmet.2012.02.001.
[42] Araiz, C., Yan, A., Bettedi, L., Samuelson, I., Virtue, S., McGavigan, A.K., et al.,
2019 Apr 4. Enhanced b-adrenergic signalling underlies an age-dependent
beneficial metabolic effect of PI3K p110a inactivation in adipose tissue. Na-
ture Communications 10(1):1546. https://doi.org/10.1038/s41467-019-
09514-1.
[43] Fischer, A.W., Csikasz, R.I., von Essen, G., Cannon, B., Nedergaard, J., 2016.
No insulating effect of obesity. American Journal of Physiology e Endocri-
nology and Metabolism 311(1):E202eE213. https://doi.org/10.1152/
ajpendo.00093.2016.
[44] Gomez-Hernandez, A., Lopez-Pastor, A.R., Rubio-Longas, C., Majewski, P.,
Beneit, N., Viana-Huete, V., et al., 2020. Specific knockout of p85a in brown
adipose tissue induces resistance to high-fat dieteinduced obesity and its
metabolic complications in male mice. Molecular Metabolism 31:1e13.
https://doi.org/10.1016/j.molmet.2019.10.010.
[45] Berbeé, J.F.P., Boon, M.R., Khedoe, P.P.S.J., Bartelt, A., Schlein, C.,
Worthmann, A., et al., 2015. Brown fat activation reduces hyper-
cholesterolaemia and protects from atherosclerosis development. Nature
Communications 6:6356. https://doi.org/10.1038/ncomms7356.
[46] Dong, M., Yang, X., Lim, S., Cao, Z., Honek, J., Lu, H., et al., 2013. Cold
exposure promotes atherosclerotic plaque growth and instability via UCP1-
dependent lipolysis. Cell Metabolism 18(1):118e129. https://doi.org/
10.1016/j.cmet.2013.06.003.
[47] Lee, E.Y., Sakurai, K., Zhang, X., Toda, C., Tanaka, T., Jiang, M., et al., 2015.
Unsuppressed lipolysis in adipocytes is linked with enhanced gluconeogenesis
and altered bile acid physiology in Insr(P1195L/þ) mice fed high-fat-diet.
Scientific Reports 5:17565. https://doi.org/10.1038/srep17565.MOLECULAR METABOLISM 40 (2020) 101020
mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
www.molecularmetabolism.com
